甲状腺眼病中的眼表面疾病：叙述性综述。
Ocular surface disease in thyroid eye disease: A narrative review.
机构信息
Department of Ophthalmology, Walter Reed National Military Medical Center, Bethesda, MD, United States.
Department of Ophthalmology and Visual Sciences, University of Illinois-Chicago, Chicago, IL, United States.
出版信息
Ocul Surf. 2022 Apr;24:67-73. doi: 10.1016/j.jtos.2022.02.001. Epub 2022 Feb 12.
Abstract
Ocular surface disease (OSD) in the setting of thyroid eye disease (TED) is traditionally thought of as a natural consequence of anatomical changes such as proptosis and corneal exposure. However, a growing body of research suggests that ocular surface inflammation and multi-factorial changes to the homeostasis of the ocular surface contribute substantially to the OSD seen in TED patients. In this paper we review the existing literature which highlights the work and existing theories underlying this new paradigm shift.
摘要
甲状腺相关眼病（TED）患者的眼表疾病（OSD）通常被认为是眼球突出和角膜暴露等解剖结构改变的自然结果。然而，越来越多的研究表明，眼表炎症和眼表稳态的多因素变化对 TED 患者的 OSD 有重要影响。本文综述了现有文献，重点介绍了这一新范式转变背后的工作和现有理论。
相似文献
1
Ocular surface disease in thyroid eye disease: A narrative review.甲状腺眼病中的眼表面疾病：叙述性综述。
Ocul Surf. 2022 Apr;24:67-73. doi: 10.1016/j.jtos.2022.02.001. Epub 2022 Feb 12.
2
Systematic review of ocular surface treatments in the setting of thyroid eye disease.甲状腺眼病背景下眼表治疗的系统评价
Front Ophthalmol (Lausanne). 2024 Jun 12;4:1352355. doi: 10.3389/fopht.2024.1352355. eCollection 2024.
3
[Tarsorrhaphy in rehabilitation of patients with thyroid eye disease].[睑裂缝合术在甲状腺眼病患者康复中的应用]
Vestn Oftalmol. 2021;137(5):47-51. doi: 10.17116/oftalma202113705147.
4
[Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].[甲状腺眼病的发病机制——针对促甲状腺激素受体的自身免疫能解释所有病例吗？]
Endokrynol Pol. 2011;62 Suppl 1:1-7.
5
Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?甲状腺眼病的发病机制——抗 TSH 受体自身免疫能否解释所有病例？
Endokrynol Pol. 2010 Mar-Apr;61(2):222-7.
6
A retrospective study of pediatric thyroid eye disease: the Asian experience.回顾性研究儿科甲状腺眼病：亚洲经验。
Orbit. 2022 Feb;41(1):69-78. doi: 10.1080/01676830.2020.1831550. Epub 2020 Oct 15.
7
Characteristics of Diabetic and Nondiabetic Patients With Thyroid Eye Disease in the United States: A Claims-Based Analysis.美国糖尿病和非糖尿病甲状腺眼病患者的特征：基于索赔的分析。
Endocr Pract. 2022 Feb;28(2):159-164. doi: 10.1016/j.eprac.2021.11.080. Epub 2021 Nov 12.
8
Acute thyroid eye disease (TED): principles of medical and surgical management.急性甲状腺眼病（TED）：医学和手术治疗原则。
Eye (Lond). 2013 Mar;27(3):308-19. doi: 10.1038/eye.2012.284. Epub 2013 Feb 15.
9
Subjective versus objective dry eye disease in patients with moderate-severe thyroid eye disease.中重度甲状腺眼病患者的主观与客观干眼症。
Ocul Surf. 2018 Oct;16(4):458-462. doi: 10.1016/j.jtos.2018.07.003. Epub 2018 Jul 7.
10
Prevalence of thyroid eye disease in Graves' disease: A meta-analysis and systematic review.Graves 病伴甲状腺眼病的患病率：Meta 分析和系统评价。
Clin Endocrinol (Oxf). 2020 Oct;93(4):363-374. doi: 10.1111/cen.14296. Epub 2020 Aug 10.
引用本文的文献
1
Emerging Age-Specific Therapeutic Approaches for Dry Eye Disease.针对干眼症的新兴年龄特异性治疗方法。
J Clin Med. 2025 Jun 11;14(12):4147. doi: 10.3390/jcm14124147.
2
Sleep quality and its determinants in patients with thyroid eye disease: a cross-sectional study.甲状腺眼病患者的睡眠质量及其决定因素：一项横断面研究。
Eur J Med Res. 2025 Jun 3;30(1):446. doi: 10.1186/s40001-025-02691-4.
3
The role of IL-6 in thyroid eye disease: an update on emerging treatments.白细胞介素-6在甲状腺眼病中的作用：新兴治疗方法的最新进展
Front Ophthalmol (Lausanne). 2025 Apr 14;5:1544436. doi: 10.3389/fopht.2025.1544436. eCollection 2025.
4
Relationship between myopia and diagnosis rates of dry eye disease and related indicators: a systematic review and meta-analysis.近视与干眼病诊断率及相关指标的关系：一项系统评价与Meta分析
Front Med (Lausanne). 2025 Mar 27;12:1541304. doi: 10.3389/fmed.2025.1541304. eCollection 2025.
5
Overview of Dry Eye Disease for Primary Care Physicians.基层医疗医生的干眼病概述
Medicina (Kaunas). 2025 Mar 6;61(3):460. doi: 10.3390/medicina61030460.
6
Predictive modeling of graves' orbitopathy activity based on meibomian glands analysis using in vivo confocal microscopy.基于体内共聚焦显微镜下睑板腺分析的格雷夫斯眼眶病活动预测模型
BMC Endocr Disord. 2025 Mar 26;25(1):83. doi: 10.1186/s12902-025-01895-3.
7
Research progress on the immune mechanism of thyroid-related eye disease combined with dry eye.甲状腺相关性眼病合并干眼免疫机制的研究进展
J Ophthalmic Inflamm Infect. 2025 Mar 10;15(1):23. doi: 10.1186/s12348-025-00477-7.
8
Eyeball descending identification using MRI-based spatial coordinates in thyroid-associated orbitopathy patients with unilateral upper eyelid retraction.基于MRI空间坐标的眼球下降识别在单侧上睑退缩的甲状腺相关性眼病患者中的应用
Quant Imaging Med Surg. 2025 Feb 1;15(2):1287-1296. doi: 10.21037/qims-24-1659. Epub 2025 Jan 9.
9
Ocular surface disease index in Graves' orbitopathy: a cross-sectional study.格雷夫斯眼眶病的眼表疾病指数：一项横断面研究。
Front Endocrinol (Lausanne). 2024 Dec 5;15:1428185. doi: 10.3389/fendo.2024.1428185. eCollection 2024.
10
A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.甲状腺眼病发病机制的全面综述：从免疫失调到新的诊断和治疗方法。
Int J Mol Sci. 2024 Oct 29;25(21):11628. doi: 10.3390/ijms252111628.
本文引用的文献
1
Evaluation of Meibomian Gland Loss and Ocular Surface Changes in Patients with Mild and Moderate-to-Severe Graves' Ophthalmopathy.轻度及中重度格雷夫斯眼病患者睑板腺缺失及眼表变化的评估
Semin Ophthalmol. 2022 Apr 3;37(3):271-276. doi: 10.1080/08820538.2021.1937662. Epub 2021 Jul 30.
2
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.2021 年欧洲 Graves 眼病专家组（EUGOGO）Graves 眼病医学管理临床实践指南。
Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479.
3
Ocular Surface Changes in Patients with Thyroid Eye Disease: An Observational Clinical Study.甲状腺眼病患者的眼表变化：一项观察性临床研究。
Clin Ophthalmol. 2021 Jun 15;15:2481-2488. doi: 10.2147/OPTH.S317708. eCollection 2021.
4
Tear film break-up patterns in thyroid eye disease.甲状腺眼病的泪膜破裂模式。
Sci Rep. 2021 Mar 5;11(1):5288. doi: 10.1038/s41598-021-84661-4.
5
Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases.甲状腺相关眼病的临床特征和临床病程：3620 例中国病例的系列病例。
Eye (Lond). 2021 Aug;35(8):2294-2301. doi: 10.1038/s41433-020-01246-7. Epub 2020 Nov 2.
6
Comparison of two regimens for patients with thyroid-associated ophthalmopathy receiving intravenous methyl prednisolone: A single center prospective randomized trial.甲状腺相关性眼病患者静脉注射甲泼尼龙两种治疗方案的比较：一项单中心前瞻性随机试验。
Exp Ther Med. 2020 Dec;20(6):153. doi: 10.3892/etm.2020.9282. Epub 2020 Oct 6.
7
Investigation of Meibomian Gland Function and Dry Eye Disease in Patients with Graves' Ophthalmopathy.格雷夫斯眼病患者睑板腺功能及干眼疾病的调查
J Clin Med. 2020 Aug 31;9(9):2814. doi: 10.3390/jcm9092814.
8
Natural history of inflammatory and non-inflammatory dry eye in thyroid eye disease.甲状腺眼病中炎症性和非炎症性干眼的自然病程。
Orbit. 2021 Oct;40(5):389-393. doi: 10.1080/01676830.2020.1814352. Epub 2020 Aug 26.
9
Videographic Analysis of Blink Dynamics following Upper Eyelid Blepharoplasty and Its Association with Dry Eye.上睑成形术后眨眼动力学的视频图像分析及其与干眼的关联
Plast Reconstr Surg Glob Open. 2020 Jul 21;8(7):e2991. doi: 10.1097/GOX.0000000000002991. eCollection 2020 Jul.
10
Teprotumumab for the Treatment of Active Thyroid Eye Disease.特罗特鲁单抗治疗活动性甲状腺眼病。
N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434.
Zotero 插件